Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini-CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microvast Powers the Next Generation of Electric Commercial Vehicles with Groundbreaking Battery Technology at IAA Transportation 202416.9.2024 19:11:00 CEST | Press release
Microvast Holdings, Inc. (NASDAQ: MVST) (“Microvast”, the “Company”, “we” or “our”), a technology innovator that designs, develops, and manufactures lithium-ion battery solutions, is advancing the adoption of electric commercial vehicles by launching its latest high-performance battery solutions at IAA Transportation 2024. The new lineup includes the introduction of silicon-based HnSO Cells, Lithium Titanate Oxide (LTO) Cells, and the third-generation MV-I Pack, offering an unprecedented combination of energy density, safety, and sustainability. Microvast’s advanced battery solutions are designed to meet the rigorous energy demands of commercial transportation, enabling manufacturers to accelerate their shift to cleaner, more efficient electric powertrains. Technological highlights and new products at IAA Transportation 2024: HnSO Cells (introduction of silicon-based cell technology): With an energy density of 300 Wh/kg, these cells provide high energy density, long cycle life (exceedi
IonQ Selected to Present at Fast Company’s 2024 Innovation Festival16.9.2024 18:24:00 CEST | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced its participation in Fast Company Innovation Festival, taking place September 16-19 in New York City. Live and in person, the 2024 Fast Company Innovation Festival will convene thousands of makers and innovators from across the globe for four days of inspired conversation, purposeful networking, and meaningful takeaways. This year’s speakers include Satya Nadella, CEO of Microsoft, Netflix Co-CEO Ted Sarandos, Ryan Reynolds, producer, actor and entrepreneur, Lin-Manuel Miranda, award-winning songwriter, actor, producer and director, Jose Andres, Founder, Jose Andres Group, World Central Kitchen and Lina Khan, Chair Federal Trade commission, among others. Throughout the Innovation Festival, Fast Company focuses on highlighting the most innovative and fast-moving trends in technology. The publication highlighted the quantum computing session from amongst 100 sessions as an exciting panel to watch in their arti
BioDuro-Sundia Appoints Dr. Armin Spura as New Chief Executive Officer16.9.2024 18:00:00 CEST | Press release
BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the appointment of Dr. Armin Spura as its new Chief Executive Officer. Dr. Spura brings over two decades of experience in the life sciences and biotechnology sectors, with a proven track record of driving growth and innovation across global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916598040/en/ Armin Spura, PhD, CEO, BioDuro-Sundia (Photo: Business Wire) Dr. Spura joins BioDuro-Sundia from Crown Bioscience, where he served as the CEO for nearly five years, guiding the company through significant growth and strategic development. Throughout his career, Dr. Spura has held senior leadership positions at several well-known organizations such as Thermo Fisher Scientific, WuXi NEXTCODE, CareDx and Ion Torrent. He also holds various advisory roles, serving as the chair of the board of directors
NIQ Unveils Groundbreaking AI Tools for CPG Brands at FastCompany Innovation Festival 2024 Providing Human-Powered Insights at the Speed of AI16.9.2024 17:10:00 CEST | Press release
NielsenIQ (NIQ), the world’s leading global consumer intelligence company, announced two breakthroughs in artificial intelligence that further validate its leadership position. BASES AI and the CPG industry’s first large language model will help NIQ clients harness the power of responsible AI to drive innovation and grow market share. NIQ will also be speaking about AI trends in consumer buying intelligence and innovation at a panel on Thursday, September 19th at 2:20pm ET titled “Does AI Know What We Truly Want? How Synthetic Respondents Are Disrupting Product Innovation.” BASES AI is a platform that uses consumer-permissioned data on consumption patterns across hundreds of thousands of households to mimic consumer behavior. The platform has access to data in real time, allowing it to create large panels of synthetic respondents to replicate trusted market research techniques and methodologies in a fraction of the time. Instead of days or weeks to gather human feedback, BASES AI can p
ProAmpac Supercharges MAKR: Industry First, Next Generation, Online Configurator for Effortless Packaging Design16.9.2024 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, proudly introduces its newest version of MAKR by DASL— an innovative online pouch configurator powered by the 3D Source Configuration Platform. Utilizing Unreal Engine, this powerful tool improves the user interface and eases graphic development, empowering users to seamlessly design custom, high-quality, digital flexible packaging prototypes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916704012/en/ MAKR Screen (Photo: Business Wire) Sal Pellingra, vice president of global package design, applications, and business development at ProAmpac, explains, “MAKR by DASL revolutionizes virtual prototyping by providing a quick and easy platform to design packaging online without complicated software or external resources. MAKR is an industry-first, user-friendly, online flexible packaging design tool.” Key Features: Format Selection: Customers choose from a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom